2.49
price up icon7.33%   0.17
after-market After Hours: 2.48 -0.01 -0.40%
loading
Cabaletta Bio Inc stock is traded at $2.49, with a volume of 5.30M. It is up +7.33% in the last 24 hours and up +35.33% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.32
Open:
$2.43
24h Volume:
5.30M
Relative Volume:
2.23
Market Cap:
$227.75M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.50
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+2.05%
1M Performance:
+35.33%
6M Performance:
+102.44%
1Y Performance:
-40.86%
1-Day Range:
Value
$2.24
$2.58
1-Week Range:
Value
$2.2301
$3.34
52-Week Range:
Value
$0.9857
$5.46

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Name
Cabaletta Bio Inc
Name
Phone
(267) 759-3100
Name
Address
2929 ARCH STREET, PHILADELPHIA, PA
Name
Employee
167
Name
Twitter
@CabalettaBio
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CABA
Cabaletta Bio Inc
2.49 212.20M 0 -67.68M -54.24M -1.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-25 Resumed Jefferies Buy
Dec-20-24 Downgrade Evercore ISI Outperform → In-line
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Oct-10-24 Initiated UBS Buy
Feb-05-24 Initiated Jefferies Buy
Nov-29-23 Initiated William Blair Outperform
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Oct-19-23 Initiated Stifel Buy
Sep-05-23 Initiated Citigroup Buy
Jul-18-23 Initiated Guggenheim Buy
Jan-27-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-30-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-08-21 Initiated Wells Fargo Overweight
Oct-19-21 Resumed Morgan Stanley Overweight
Jun-30-21 Initiated Mizuho Buy
Jan-08-21 Initiated Chardan Capital Markets Buy
Oct-13-20 Initiated H.C. Wainwright Buy
Nov-19-19 Initiated Cowen Outperform
Nov-19-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Morgan Stanley Overweight
View All

Cabaletta Bio Inc Stock (CABA) Latest News

pulisher
11:19 AM

Measuring Cabaletta Bio Inc.’s beta against major indicesTrade Signal Summary & Daily Profit Focused Stock Screening - newser.com

11:19 AM
pulisher
09:07 AM

Why Cabaletta Bio Inc. stock could rally in 2025July 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com

09:07 AM
pulisher
08:26 AM

Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com

08:26 AM
pulisher
05:26 AM

Visualizing Cabaletta Bio Inc. stock with heatmapsQuarterly Profit Summary & Long-Term Capital Growth Ideas - newser.com

05:26 AM
pulisher
03:40 AM

Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com

03:40 AM
pulisher
Oct 12, 2025

Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada

Oct 11, 2025
pulisher
Oct 10, 2025

Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews

Oct 10, 2025
pulisher
Oct 10, 2025

Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times

Oct 09, 2025
pulisher
Oct 09, 2025

What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

What candlestick patterns are forming on Cabaletta Bio Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Published on: 2025-10-09 01:46:57 - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com

Oct 07, 2025
pulisher
Oct 07, 2025

Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha

Oct 07, 2025
pulisher
Oct 06, 2025

Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN

Oct 05, 2025
pulisher
Sep 30, 2025

Published on: 2025-10-01 06:55:18 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN

Sep 29, 2025

Cabaletta Bio Inc Stock (CABA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):